Atrion (ATRI) vs. The Competition Head to Head Analysis
Atrion (NASDAQ: ATRI) is one of 83 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its competitors? We will compare Atrion to related companies based on the strength of its analyst recommendations, risk, profitability, earnings, valuation, dividends and institutional ownership.
Valuation & Earnings
This table compares Atrion and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Atrion||$143.49 million||$27.58 million||31.08|
|Atrion Competitors||$991.62 million||$72.91 million||219.16|
Atrion pays an annual dividend of $4.80 per share and has a dividend yield of 0.9%. Atrion pays out 26.6% of its earnings in the form of a dividend. As a group, “Medical Equipment, Supplies & Distribution” companies pay a dividend yield of 0.9% and pay out 30.5% of their earnings in the form of a dividend. Atrion has raised its dividend for 15 consecutive years. Atrion is clearly a better dividend stock than its competitors, given its higher yield and lower payout ratio.
Insider and Institutional Ownership
58.8% of Atrion shares are owned by institutional investors. Comparatively, 65.3% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 23.1% of Atrion shares are owned by insiders. Comparatively, 12.4% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk and Volatility
Atrion has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Atrion’s competitors have a beta of 0.97, suggesting that their average stock price is 3% less volatile than the S&P 500.
This is a breakdown of current recommendations for Atrion and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 9.41%. Given Atrion’s competitors higher possible upside, analysts plainly believe Atrion has less favorable growth aspects than its competitors.
This table compares Atrion and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Atrion Company Profile
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology. Its cardiovascular product, MPS2 Myocardial Protection System (MPS2), is the system used in open-heart surgery that delivers fluids and medications, mixes critical drugs and controls temperature, pressure and other variables. The Company manufactures specialized medical devices that disinfect contact lenses. Its other medical and non-medical product lines consist of instrumentation and associated disposables.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.